|
Jul 24
|
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
|
|
Jul 24
|
Dystrophic Epidermolysis Bullosa Market Analysis and Forecast, 2025-2035: Topical Therapies Dominate DEB Market as Vyjuvek Secures Leading Position
|
|
Jul 10
|
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
|
|
Jul 9
|
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
|
|
Jul 7
|
Exploring High Growth Tech Stocks In The US Market
|
|
Jul 7
|
High Insider Ownership In 3 Promising Growth Companies
|
|
Jul 2
|
Krystal Biotech, Inc.'s (NASDAQ:KRYS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
|
|
Jun 27
|
3 Promising Genomics Stocks to Keep an Eye On in 2025
|
|
Jun 25
|
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study
|
|
Jun 25
|
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?
|
|
Jun 24
|
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
|
|
Apr 17
|
Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
|
|
Apr 8
|
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?
|
|
Apr 7
|
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
|
|
Apr 7
|
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
|
|
Feb 24
|
Why Krystal Biotech (KRYS) Might be Well Poised for a Surge
|
|
Feb 24
|
Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term
|
|
Feb 21
|
Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know
|
|
Feb 20
|
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
|
|
Feb 20
|
3 US Growth Companies With High Insider Ownership Expecting Up To 68% Earnings Growth
|